Veru Inc. (NASDAQ: VERU) stock fell -2.65% on Monday to $6.24 against a previous-day closing price of $6.41. With 2.29 million shares changed hands, the volume of the stock remained lighter than its average volume of 4.29 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $6.41 whereas the lowest price it dropped to was $6.01. The 52-week range on VERU shows that it touched its highest point at $24.55 and its lowest point at $4.34 during that stretch. It currently has a 1-year price target of $15.75. Beta for the stock currently stands at -0.26.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VERU was down-trending over the past week, with a drop of -0.32%, but this was up by 30.54% over a month. Three-month performance dropped to -43.88% while six-month performance fell -60.80%. The stock gained 17.51% in the past year, while it has gained 18.18% so far this year. A look at the trailing 12-month EPS for VERU yields -1.04 with Next year EPS estimates of -1.04. For the next quarter, that number is -0.38. This implies an EPS growth rate of -33.30% for this year and 25.70% for next year.
Float and Shares Shorts:
At present, 80.33 million VERU shares are outstanding with a float of 61.13 million shares on hand for trading. On Oct 13, 2022, short shares totaled 16.72 million, which was 20.86% higher than short shares on Sep 14, 2022. In addition to Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D. as the firm’s Chairman, Pres & CEO, Dr. Harry Fisch F.A.C.S., M.D. serves as its Vice Chairman & Chief Corp. Officer.
Through their ownership of 55.61% of VERU’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 33.92% of VERU, in contrast to 21.80% held by mutual funds. Shares owned by individuals account for 11.98%. As the largest shareholder in VERU with 7.33% of the stake, Morgan Stanley & Co. LLC holds 5,908,811 shares worth 5,908,811. A second-largest stockholder of VERU, Perceptive Advisors LLC, holds 3,893,000 shares, controlling over 4.83% of the firm’s shares. Candriam Belgium SA is the third largest shareholder in VERU, holding 3,781,148 shares or 4.69% stake. With a 2.39% stake in VERU, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,923,707 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 1.83% of VERU stock, is the second-largest Mutual Fund holder. It holds 1,477,319 shares valued at 7.8 million. Vanguard Consumer Staples Index F holds 1.01% of the stake in VERU, owning 813,484 shares worth 4.3 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VERU since 4 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VERU analysts setting a high price target of $22.00 and a low target of $3.00, the average target price over the next 12 months is $15.75. Based on these targets, VERU could surge 252.56% to reach the target high and fall by -51.92% to reach the target low. Reaching the average price target will result in a growth of 152.4% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. VERU will report FY 2023 earnings on 12/14/2023. Analysts have provided yearly estimates in a range of -$1.11 being high and -$1.53 being low. For VERU, this leads to a yearly average estimate of -$1.40. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Veru Inc. surprised analysts by -$0.21 when it reported -$0.51 EPS against a consensus estimate of -$0.30. The surprise factor in the prior quarter was -$0.12. Based on analyst estimates, the high estimate for the next quarter is -$0.34 and the low estimate is -$0.41. The average estimate for the next quarter is thus -$0.38.
Summary of Insider Activity:
Insiders traded VERU stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 4 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 100,000 while 100,000 shares were sold.